-transparent.png){kind=logo}
Nineteen previously treated refractory ovarian cancer patients, including 17 who had received standard-dose cisplatin regimens, were treated in a phase II trial with high-dose cisplatin (40 mg/m2 daily for five days with cycles administered every 28 to 35 days). Objective responses were achieved in 6/19 (32%) patients while eight patients had minor responses or stable disease. The median duration of survival from the start of salvage chemotherapy was 12 months for all patients, and 16 months for responding patients. The dose-limiting toxicity was peripheral neuropathy with 37% of patients having severe paresthesias or ataxia. These results indicate that the dose of cisplatin may be an important factor in improving survival in ovarian cancer patients.
R F Ozols, and
Y Ostchega, and
C E Myers, and
R C Young
July 1987,
Nihon Sanka Fujinka Gakkai zasshi,
R F Ozols, and
Y Ostchega, and
C E Myers, and
R C Young
October 1985,
Journal of clinical oncology : official journal of the American Society of Clinical Oncology,
R F Ozols, and
Y Ostchega, and
C E Myers, and
R C Young
June 1986,
Cancer treatment reports,
R F Ozols, and
Y Ostchega, and
C E Myers, and
R C Young
December 1985,
Seminars in oncology,
R F Ozols, and
Y Ostchega, and
C E Myers, and
R C Young
January 1987,
Journal of clinical pharmacology,
R F Ozols, and
Y Ostchega, and
C E Myers, and
R C Young
January 1987,
Cancer chemotherapy and pharmacology,
R F Ozols, and
Y Ostchega, and
C E Myers, and
R C Young
November 2011,
Seminars in nephrology,
R F Ozols, and
Y Ostchega, and
C E Myers, and
R C Young
October 2015,
Advances in therapy,
R F Ozols, and
Y Ostchega, and
C E Myers, and
R C Young
June 1996,
American journal of obstetrics and gynecology,
R F Ozols, and
Y Ostchega, and
C E Myers, and
R C Young
January 2005,
Clinical drug investigation,
